| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Methamphetamine | 19 | 2015 | 48 | 5.900 |
Why?
|
| Central Nervous System Stimulants | 13 | 2013 | 52 | 3.270 |
Why?
|
| Globus Pallidus | 11 | 2013 | 31 | 3.130 |
Why?
|
| Rats, Sprague-Dawley | 38 | 2016 | 453 | 2.940 |
Why?
|
| Rats | 38 | 2015 | 858 | 2.710 |
Why?
|
| Motor Activity | 14 | 2016 | 369 | 2.700 |
Why?
|
| Conditioning, Operant | 9 | 2015 | 15 | 2.700 |
Why?
|
| Animals | 50 | 2020 | 4577 | 2.440 |
Why?
|
| Behavior, Animal | 9 | 2015 | 105 | 2.210 |
Why?
|
| Mianserin | 6 | 2016 | 15 | 2.140 |
Why?
|
| Morphine | 7 | 2013 | 79 | 1.920 |
Why?
|
| Dopamine Agonists | 5 | 2020 | 46 | 1.900 |
Why?
|
| Cocaine | 5 | 2017 | 46 | 1.780 |
Why?
|
| Dopamine | 6 | 2020 | 156 | 1.750 |
Why?
|
| Nucleus Accumbens | 8 | 2015 | 25 | 1.750 |
Why?
|
| Impulsive Behavior | 5 | 2016 | 21 | 1.690 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 5 | 2015 | 16 | 1.660 |
Why?
|
| Antidepressive Agents, Tricyclic | 4 | 2016 | 23 | 1.420 |
Why?
|
| Association Learning | 5 | 2013 | 14 | 1.410 |
Why?
|
| Brain | 8 | 2017 | 1687 | 1.370 |
Why?
|
| Synaptic Transmission | 5 | 2015 | 46 | 1.300 |
Why?
|
| Cerebral Cortex | 3 | 2015 | 195 | 1.260 |
Why?
|
| HIV-1 | 4 | 2015 | 440 | 1.250 |
Why?
|
| Cocaine-Related Disorders | 3 | 2017 | 18 | 1.210 |
Why?
|
| Neurons | 8 | 2014 | 374 | 1.200 |
Why?
|
| Choice Behavior | 3 | 2015 | 56 | 1.160 |
Why?
|
| Behavior, Addictive | 2 | 2020 | 11 | 1.140 |
Why?
|
| Motivation | 4 | 2015 | 100 | 1.110 |
Why?
|
| Limbic System | 3 | 2013 | 11 | 1.090 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 3 | 2017 | 10 | 1.080 |
Why?
|
| Male | 41 | 2016 | 15637 | 1.070 |
Why?
|
| Prefrontal Cortex | 4 | 2015 | 152 | 1.060 |
Why?
|
| Benzothiazoles | 2 | 2016 | 20 | 0.990 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 2 | 2014 | 2 | 0.980 |
Why?
|
| Receptors, Metabotropic Glutamate | 3 | 2013 | 18 | 0.980 |
Why?
|
| Parkinson Disease, Secondary | 3 | 2014 | 29 | 0.920 |
Why?
|
| Corpus Striatum | 5 | 2016 | 111 | 0.910 |
Why?
|
| Receptors, AMPA | 3 | 2013 | 13 | 0.910 |
Why?
|
| Self Administration | 10 | 2015 | 36 | 0.890 |
Why?
|
| Calcium Channels, L-Type | 2 | 2014 | 58 | 0.890 |
Why?
|
| Action Potentials | 6 | 2015 | 137 | 0.870 |
Why?
|
| Substance-Related Disorders | 4 | 2015 | 104 | 0.860 |
Why?
|
| Drug-Seeking Behavior | 3 | 2015 | 6 | 0.860 |
Why?
|
| Risk-Taking | 3 | 2016 | 32 | 0.760 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2011 | 9 | 0.750 |
Why?
|
| Parkinson Disease | 4 | 2020 | 1164 | 0.730 |
Why?
|
| HIV Infections | 3 | 2017 | 980 | 0.710 |
Why?
|
| Cues | 5 | 2015 | 61 | 0.710 |
Why?
|
| Analgesics, Opioid | 5 | 2013 | 215 | 0.680 |
Why?
|
| Self Stimulation | 3 | 2016 | 12 | 0.680 |
Why?
|
| Antiparkinson Agents | 3 | 2017 | 130 | 0.660 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 3 | 2013 | 15 | 0.650 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 3 | 2008 | 27 | 0.650 |
Why?
|
| Proto-Oncogene Proteins c-fos | 4 | 2007 | 11 | 0.620 |
Why?
|
| Cortical Excitability | 1 | 2015 | 2 | 0.560 |
Why?
|
| Disease Models, Animal | 7 | 2015 | 726 | 0.540 |
Why?
|
| Pyridines | 2 | 2012 | 42 | 0.540 |
Why?
|
| Analysis of Variance | 6 | 2012 | 321 | 0.530 |
Why?
|
| Basal Forebrain | 1 | 2015 | 2 | 0.530 |
Why?
|
| GABAergic Neurons | 1 | 2015 | 6 | 0.530 |
Why?
|
| Reward | 6 | 2015 | 34 | 0.520 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 1 | 2014 | 1 | 0.510 |
Why?
|
| Drug Inverse Agonism | 1 | 2014 | 2 | 0.510 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 2 | 2013 | 3 | 0.510 |
Why?
|
| Neurocognitive Disorders | 1 | 2015 | 19 | 0.510 |
Why?
|
| Extinction, Psychological | 2 | 2011 | 15 | 0.500 |
Why?
|
| Fendiline | 1 | 2013 | 2 | 0.480 |
Why?
|
| Space Perception | 1 | 2013 | 28 | 0.470 |
Why?
|
| Calcium Channel Blockers | 1 | 2013 | 37 | 0.470 |
Why?
|
| Dopaminergic Neurons | 1 | 2014 | 44 | 0.470 |
Why?
|
| Brain Chemistry | 1 | 2013 | 47 | 0.460 |
Why?
|
| Hyperkinesis | 1 | 2013 | 11 | 0.450 |
Why?
|
| Oxidopamine | 5 | 2016 | 24 | 0.450 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2016 | 437 | 0.450 |
Why?
|
| Amphetamine | 3 | 2007 | 13 | 0.450 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 217 | 0.440 |
Why?
|
| Morphine Dependence | 1 | 2012 | 2 | 0.440 |
Why?
|
| Serotonin Antagonists | 1 | 2012 | 19 | 0.440 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2012 | 25 | 0.430 |
Why?
|
| Indoles | 1 | 2012 | 48 | 0.430 |
Why?
|
| Probability Learning | 1 | 2012 | 1 | 0.430 |
Why?
|
| Receptors, GABA-B | 1 | 2011 | 3 | 0.410 |
Why?
|
| Baclofen | 1 | 2011 | 15 | 0.400 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2012 | 23 | 0.400 |
Why?
|
| GABA-B Receptor Agonists | 1 | 2010 | 2 | 0.390 |
Why?
|
| Electric Stimulation | 4 | 2015 | 83 | 0.380 |
Why?
|
| Receptors, Opioid, mu | 3 | 2008 | 6 | 0.370 |
Why?
|
| Glutamic Acid | 2 | 2006 | 32 | 0.360 |
Why?
|
| Ventral Tegmental Area | 2 | 2014 | 12 | 0.340 |
Why?
|
| Oncogene Proteins v-fos | 1 | 2008 | 1 | 0.330 |
Why?
|
| Basal Ganglia | 1 | 2008 | 29 | 0.330 |
Why?
|
| Amphetamine-Related Disorders | 3 | 2013 | 10 | 0.330 |
Why?
|
| Receptors, Serotonin, 5-HT2 | 1 | 2008 | 1 | 0.320 |
Why?
|
| Time Factors | 6 | 2013 | 1618 | 0.320 |
Why?
|
| Mental Disorders | 1 | 2010 | 140 | 0.320 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2020 | 18 | 0.310 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 7 | 0.300 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 2006 | 2 | 0.290 |
Why?
|
| Conditioning, Classical | 1 | 2006 | 7 | 0.290 |
Why?
|
| Social Environment | 1 | 2006 | 79 | 0.280 |
Why?
|
| Narcotics | 1 | 2006 | 34 | 0.280 |
Why?
|
| Immunohistochemistry | 5 | 2012 | 391 | 0.270 |
Why?
|
| Blotting, Western | 3 | 2013 | 170 | 0.260 |
Why?
|
| Hippocampus | 2 | 2007 | 274 | 0.260 |
Why?
|
| Pyramidal Cells | 2 | 2015 | 44 | 0.260 |
Why?
|
| Humans | 14 | 2020 | 29361 | 0.250 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2004 | 7 | 0.250 |
Why?
|
| Neural Pathways | 3 | 2014 | 83 | 0.250 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2002 | 13 | 0.220 |
Why?
|
| Maze Learning | 1 | 2002 | 16 | 0.220 |
Why?
|
| Prosencephalon | 1 | 2002 | 8 | 0.220 |
Why?
|
| Excitatory Amino Acids | 1 | 2002 | 1 | 0.220 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2002 | 3 | 0.210 |
Why?
|
| Serotonin Receptor Agonists | 2 | 2013 | 9 | 0.200 |
Why?
|
| Receptors, Serotonin | 2 | 2012 | 21 | 0.200 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2020 | 5 | 0.190 |
Why?
|
| Drug Administration Routes | 2 | 2013 | 12 | 0.180 |
Why?
|
| Memory | 2 | 2013 | 318 | 0.180 |
Why?
|
| Delay Discounting | 2 | 2016 | 24 | 0.170 |
Why?
|
| Iontophoresis | 3 | 2004 | 7 | 0.170 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2017 | 16 | 0.150 |
Why?
|
| Sympatholytics | 2 | 2008 | 14 | 0.150 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2017 | 54 | 0.140 |
Why?
|
| Levodopa | 1 | 2017 | 142 | 0.140 |
Why?
|
| Rats, Transgenic | 1 | 2015 | 21 | 0.140 |
Why?
|
| Random Allocation | 1 | 2016 | 146 | 0.140 |
Why?
|
| Rats, Inbred F344 | 1 | 2015 | 48 | 0.140 |
Why?
|
| Benzazepines | 2 | 2006 | 8 | 0.130 |
Why?
|
| Hypothalamus | 1 | 2015 | 6 | 0.130 |
Why?
|
| Self-Control | 1 | 2015 | 7 | 0.130 |
Why?
|
| Personality Disorders | 1 | 2015 | 19 | 0.130 |
Why?
|
| Electrophysiology | 2 | 2008 | 129 | 0.130 |
Why?
|
| Biophysics | 2 | 2012 | 38 | 0.130 |
Why?
|
| Microvessels | 1 | 2014 | 16 | 0.130 |
Why?
|
| Personality | 1 | 2015 | 68 | 0.120 |
Why?
|
| Organ Culture Techniques | 1 | 2014 | 31 | 0.120 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2006 | 49 | 0.120 |
Why?
|
| Rotarod Performance Test | 1 | 2013 | 8 | 0.120 |
Why?
|
| Avoidance Learning | 1 | 2013 | 9 | 0.120 |
Why?
|
| Pyrazines | 1 | 2013 | 10 | 0.120 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2013 | 2 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 220 | 0.120 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2004 | 36 | 0.120 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2013 | 36 | 0.110 |
Why?
|
| Substantia Nigra | 1 | 2014 | 148 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2013 | 64 | 0.110 |
Why?
|
| Cytokines | 1 | 2015 | 348 | 0.110 |
Why?
|
| Aminopyridines | 1 | 2012 | 3 | 0.110 |
Why?
|
| Reinforcement Schedule | 1 | 2012 | 2 | 0.110 |
Why?
|
| Quinolines | 1 | 2012 | 16 | 0.110 |
Why?
|
| Exploratory Behavior | 1 | 2012 | 18 | 0.110 |
Why?
|
| Thiazoles | 1 | 2012 | 35 | 0.110 |
Why?
|
| Adrenergic Agents | 1 | 2012 | 2 | 0.110 |
Why?
|
| Hypoxia, Brain | 1 | 2011 | 14 | 0.100 |
Why?
|
| Refractory Period, Electrophysiological | 1 | 2011 | 6 | 0.100 |
Why?
|
| Evoked Potentials, Motor | 1 | 2011 | 10 | 0.100 |
Why?
|
| Neural Inhibition | 1 | 2011 | 10 | 0.100 |
Why?
|
| Electrodes, Implanted | 1 | 2012 | 46 | 0.100 |
Why?
|
| Motor Cortex | 1 | 2011 | 17 | 0.100 |
Why?
|
| Probability | 1 | 2011 | 94 | 0.100 |
Why?
|
| Synaptophysin | 2 | 2007 | 9 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 223 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2010 | 67 | 0.100 |
Why?
|
| Cyclopentanes | 1 | 2010 | 4 | 0.100 |
Why?
|
| Phenols | 1 | 2010 | 8 | 0.100 |
Why?
|
| beta Catenin | 1 | 2011 | 46 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2010 | 21 | 0.100 |
Why?
|
| Neuronal Plasticity | 1 | 2010 | 43 | 0.100 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 216 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 1 | 2011 | 132 | 0.090 |
Why?
|
| Brain Mapping | 1 | 2011 | 195 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2011 | 483 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 788 | 0.090 |
Why?
|
| Emotions | 1 | 2010 | 90 | 0.090 |
Why?
|
| Taste | 1 | 2008 | 4 | 0.090 |
Why?
|
| Social Behavior | 1 | 2010 | 98 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 28 | 0.080 |
Why?
|
| Photomicrography | 1 | 2008 | 1 | 0.080 |
Why?
|
| Bicuculline | 1 | 2008 | 1 | 0.080 |
Why?
|
| GABA Antagonists | 1 | 2008 | 3 | 0.080 |
Why?
|
| N-Methylaspartate | 1 | 2008 | 4 | 0.080 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2008 | 3 | 0.080 |
Why?
|
| Somatostatin | 1 | 2008 | 5 | 0.080 |
Why?
|
| Microinjections | 1 | 2008 | 6 | 0.080 |
Why?
|
| Narcotic Antagonists | 1 | 2008 | 14 | 0.080 |
Why?
|
| Catheterization | 1 | 2008 | 51 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2008 | 159 | 0.080 |
Why?
|
| Telencephalon | 1 | 2007 | 2 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2008 | 202 | 0.080 |
Why?
|
| Risk Factors | 1 | 2014 | 2446 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2008 | 174 | 0.070 |
Why?
|
| 2-Amino-5-phosphonovalerate | 1 | 2006 | 3 | 0.070 |
Why?
|
| Receptors, Glutamate | 1 | 2006 | 5 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 1 | 2006 | 13 | 0.070 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 32 | 0.070 |
Why?
|
| Injections | 1 | 2006 | 56 | 0.070 |
Why?
|
| Mental Recall | 1 | 2006 | 74 | 0.070 |
Why?
|
| Opioid-Related Disorders | 1 | 2006 | 49 | 0.070 |
Why?
|
| Alcoholism | 1 | 2005 | 83 | 0.060 |
Why?
|
| Sulpiride | 1 | 2004 | 1 | 0.060 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2004 | 1 | 0.060 |
Why?
|
| Dopamine Antagonists | 1 | 2004 | 14 | 0.060 |
Why?
|
| Time | 1 | 2004 | 18 | 0.060 |
Why?
|
| Binding Sites | 1 | 2004 | 71 | 0.060 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2004 | 83 | 0.060 |
Why?
|
| Functional Laterality | 1 | 2004 | 91 | 0.060 |
Why?
|
| Reserpine | 1 | 2002 | 1 | 0.050 |
Why?
|
| Infusion Pumps | 1 | 2002 | 16 | 0.050 |
Why?
|
| Electrochemistry | 1 | 2002 | 44 | 0.050 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 1 | 2002 | 1 | 0.050 |
Why?
|
| Evoked Potentials | 1 | 2002 | 18 | 0.050 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2002 | 34 | 0.050 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2002 | 17 | 0.050 |
Why?
|
| Cell Count | 2 | 2015 | 99 | 0.050 |
Why?
|
| United States | 1 | 2005 | 2332 | 0.040 |
Why?
|
| Intracellular Space | 1 | 2015 | 8 | 0.030 |
Why?
|
| Spleen | 1 | 2015 | 51 | 0.030 |
Why?
|
| Receptors, Endothelin | 1 | 2014 | 5 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2014 | 9 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 16 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 2014 | 24 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 2015 | 189 | 0.030 |
Why?
|
| Hypoxia | 1 | 2014 | 60 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2014 | 101 | 0.030 |
Why?
|
| Inflammation | 1 | 2015 | 345 | 0.030 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2011 | 5 | 0.030 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2011 | 17 | 0.030 |
Why?
|
| Electromyography | 1 | 2011 | 78 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 145 | 0.020 |
Why?
|
| AIDS Dementia Complex | 1 | 2011 | 41 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 112 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 299 | 0.020 |
Why?
|
| Astrocytes | 1 | 2011 | 122 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 497 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 692 | 0.020 |
Why?
|
| Dentate Gyrus | 1 | 2007 | 8 | 0.020 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2007 | 8 | 0.020 |
Why?
|
| Neostriatum | 1 | 2007 | 22 | 0.020 |
Why?
|
| Amygdala | 1 | 2007 | 50 | 0.020 |
Why?
|
| Receptor, trkB | 1 | 2006 | 3 | 0.020 |
Why?
|
| Young Adult | 1 | 2011 | 1935 | 0.020 |
Why?
|
| Adult | 1 | 2011 | 8604 | 0.010 |
Why?
|
| Middle Aged | 1 | 2011 | 9823 | 0.010 |
Why?
|
| Female | 1 | 2011 | 16211 | 0.010 |
Why?
|